MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Daniel Pozza (Author) FMUP; De Mello, RA (Author) Other; Araujo, RLC (Author) Other; Velcheti, V (Author) Other

Journal

Title: Current Genomics

Vol. 21

Pages: 372-381

ISSN: 1389-2029

Publisher: Bentham Science

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Scientific classification

CORDIS: Health sciences

FOS: Medical and Health sciences

Other information

Authenticus ID: P-00S-JEP

DOI: 10.2174/1389202921999200630144712

Abstract (EN): Background: Lung cancer (LC) development is a process that depends on genetic mutations. The DNA methylation, an important epigenetic modification, is associated with the expression of noncoding RNAs, such as microRNAs. MicroRNAs are particularly essential for cell physiology, since they play a critical role in tumor suppressor gene activity. Furthermore, epigenetic disruptions are the primary event in cell modification, being related to tumorigenesis. In this context, microRNAs can be a useful tool in the LC suppression, consequently improving prognosis and predicting treatment. Conclusion: This manuscript reviews the main microRNAs involved in LC and its potential clinical applications to improve outcomes, such as survival and better quality of life.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10